Evidence

Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial.

July 2, 2017

PUBLICATION: European Journal of Cancer. July 2017, Volume 79, Pages 98–105. AUTHORS: K.C. Aalders, A. Kuijerb, M.E. Straver, L. Slaets, S. Litiere, G. Viale, L.J. van’t Veer, A.M. Glas, M. Delorenzi, T. van Dalen, K. Tryfonidis, M.J. Piccart, F. Cardoso, E.J. Rutgers on behalf of the TRANSBIG Consortium and the MINDACT Investigators SUMMARY: 

Read more

Risk Estimations and Treatment Decisions in Early Stage Breast Cancer: Agreement Among Oncologists and the Impact of the 70-Gene Signature

April 1, 2014

PUBLICATION: Eur J Cancer. 2014 Apr;50(6):1045-54. doi: 10.1016/j.ejca.2014.01.016. Epub 2014 Feb 13. AUTHORS: Drukker C.A., van den Hout H.C., Sonke G.S., Brain E., Bonnefoi H., Cardoso F., Goldhirsch A., Harbeck N., Honkoop A.H., Koornstra R.H., van Laarhoven H.W., Portielje J.E., Schneeweiss A., Smorenburg C.H., Stouthard J., Linn S.C., Schmidt M.K. SUMMARY: Adding the 70-gene signature result significantly increased…

Read more

Prospective Cost-Effectiveness Analysis of Genomic Profiling in Breast Cancer

December 1, 2013

PUBLICATION: European Journal of Cancer. December 2013, Volume 49, Issue 18, Pages 3773–3779 AUTHORS: V.P. Retèl, M.A. Jooreb, C.A. Drukker, J.M. Bueno-de-Mesquita, M. Knauer, H. van Tinteren, S.C. Linn, W.H. van Harten SUMMARY: The total health care costs per patient were €26,786 for the 70-gene and €29,187 for AO. The quality adjusted life years yielded 12.49 and 11.88,…

Read more

The EORTC 10041/BIG 03-04 MINDACT Trial is Feasible: Results of the Pilot Phase

December 1, 2011

PUBLICATION: European Journal of Cancer, December 2011, Volume 47, Issue 18, Pages 2742–2749. AUTHORS: Emiel Rutgers, Martine J. Piccart-Gebhart, Jan Bogaerts, Suzette Delaloge, Laura Van ‘t Veer, Isabel Teresa Rubio, Giuseppe Viale, Alastair M. Thompson, Rodolfo Passalacqua, Ulrike Nitz, Anita Vindevoghel, Jean-Yves Pierga, Peter M. Ravdin, Gustavo Werutsky, Fatima Cardoso SUMMARY: The logistically complex MINDACT trial is feasible…

Read more

Cost-effectiveness of the 70-gene Signature Versus St. Gallen Guidelines and Adjuvant Online for Early Breast Cancer

May 2, 2010

PUBLICATION: Eur J Cancer. 2010 May;46(8):1382-91. doi: 10.1016/j.ejca.2010.02.035. Epub 2010 Mar 30. AUTHORS: Retèl V.P., Joore M.A., Knauer M., Linn S.C., Hauptmann M., Harten W.H. SUMMARY: Pooled analysis: he 70-gene has the highest probability of being cost-effective for a willingness to pay for a QALY higher than euro12.000. Sankt Gallen showed the highest survival rates compared to the…

Read more

Daily Clinical Practice of Fresh Tumour Tissue Freezing and Gene Expression Profiling; Logistics Pilot Study Preceding the MINDACT Trial

May 1, 2009

PUBLICATION: Eur J Cancer. 2009 May;45(7):1201-1208. doi: 10.1016/j.ejca.2009.01.004. Epub 2009 Feb 14. AUTHORS: Mook S., Bonnefoi H., Pruneri G., Larsimont D., Jaskiewicz J., Sabadell M.D., MacGrogan G., Van’t Veer L.J., Cardoso F., Rutgers E.J. SUMMARY: Tumour samples were obtained in 60 of 64 patients. Among the 60 samples, 11 contained insufficient tumour cells (

Read more